Algia Pharma Completes IND-Enabling Toxicology Study for AlgiaPak, Advancing Non-Opioid Acute Pain Treatment Toward Clinical Trials
Algia Pharma, LLC has announced the successful completion of an Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®, a hospital-grade multimodal pain management regimen designed to treat mild-to-moderate acute pain without exposing patients to the addiction risks associated with opioids. The milestone brings the company closer to submitting an IND application to the U.S. Food and Drug Administration (FDA) and advancing the investigational treatment into clinical development.
According to the company, the toxicology study was conducted in full compliance with Good Laboratory Practice (GLP) standards. Results showed that AlgiaPak was tolerated at the dose level tested, with no adverse gross pathological or histopathological findings identified in the gastrointestinal (GI) tract. These findings represent an important step in the preclinical development program as Algia prepares the regulatory documentation needed to support the proposed clinical investigation.
The company is now shifting its focus toward regulatory readiness and clinical trial preparation. Algia expects to submit its IND application to the FDA by the end of 2026. Subject to regulatory clearance, the company anticipates initiating a randomized, double-blind Phase 2a clinical trial in the first quarter of 2027. The study is expected to evaluate the safety and efficacy of AlgiaPak in patients experiencing mild-to-moderate acute pain following bunionectomy, a surgical procedure commonly used to correct a bunion deformity of the foot.
“Completing our IND-enabling toxicology study represents a crucial milestone in the development of AlgiaPak. This progress comes as we seek funding to advance the AlgiaPak clinical program toward a Phase 2a trial,” said David Steinberg, Pharm.D., J.D., co-founder and chief executive officer of Algia Pharma. “Expanding non-opioid treatment options is essential to helping patients manage acute pain while reducing reliance on opioids. We are actively finalizing our regulatory dossier and anticipate submitting the IND application for AlgiaPak to the FDA in the coming months.”
The announcement comes as healthcare providers, researchers and pharmaceutical developers continue to seek alternatives to opioid-based pain management. Although opioids remain important medicines for selected clinical situations, their potential for misuse, dependence and addiction has intensified interest in treatment strategies that can provide effective pain relief while reducing exposure to these risks.
AlgiaPak is being developed to address this need through a standardized multimodal approach that combines multiple established medicines into a single prescribing and dosing format. The company aims to make this approach easier to implement in outpatient settings, where patients may otherwise need to manage several medications with different dosing schedules after leaving a hospital or surgical facility.
IND-Enabling Toxicology Study Marks a Development Milestone
Before an investigational medicine can enter human clinical trials in the United States, sponsors generally need to submit preclinical and manufacturing information to the FDA to support the proposed investigation. IND-enabling studies help characterize a candidate’s safety profile and provide information relevant to determining whether clinical testing can proceed.
Algia’s recently completed toxicology study represents part of this process for AlgiaPak. The study was conducted in accordance with GLP standards, which establish requirements for the organization, performance, monitoring, documentation and reporting of nonclinical laboratory studies intended to support regulatory submissions.
The company reported that AlgiaPak was tolerated at the dose level tested and that investigators observed no adverse gross pathological or histopathological findings in the GI tract. Gross pathology involves examining tissues and organs for visible abnormalities, while histopathology involves microscopic examination of tissue samples to identify potential changes that may not be apparent during a visual assessment.
The reported results provide supportive preclinical information for the development program. However, the findings should be interpreted within the scope of the study. The absence of reported adverse findings in the GI tract does not establish that the regimen is free of all potential safety risks, nor does it demonstrate safety in humans. Clinical trials will be needed to evaluate tolerability, adverse events, dosing and other safety considerations in patients.
Completion of the study nevertheless allows Algia to move forward with finalizing its regulatory package and preparing for the next phase of development. The company’s planned IND submission will bring together relevant nonclinical, manufacturing and proposed clinical-study information for FDA review.
Algia’s progress also comes as the company seeks funding to support its clinical program. Advancing an investigational treatment from preclinical development into human studies requires resources for regulatory activities, clinical operations, study-site coordination, manufacturing and data collection. The availability of financing will therefore be an important consideration as the company works toward its Phase 2a objectives.
FDA Guidance Supports the Proposed Clinical Development Pathway
In December 2025, Algia announced that it had received FDA support to advance AlgiaPak toward a Phase 2 clinical trial following completion of the required IND-enabling studies. The company also reported that the agency recommended the 505(b)(2) regulatory pathway for the product.
The 505(b)(2) pathway is an established route for certain drug applications that allows a sponsor to rely, at least in part, on findings from previous FDA determinations of safety and effectiveness or on existing scientific literature, where appropriate. It can be relevant to products that incorporate previously studied active ingredients or build on established medicines in a new formulation, combination or use.
The suitability of this pathway depends on the specific product, the available evidence and the FDA’s assessment of the proposed application. For AlgiaPak, the company has identified the pathway as part of its regulatory strategy. The exact scope of evidence needed to support any eventual marketing application will depend on regulatory requirements and the results of the development program.
Algia also reported that the FDA recommended reducing the planned Phase 2 study duration from seven days to three days. According to the company, the agency broadened the initial proposed indication beyond perioperative pain to encompass all mild-to-moderate acute pain.
This broader development objective could allow Algia to investigate AlgiaPak in a wider range of acute pain settings rather than limiting its initial focus to pain associated with surgery. Acute pain can occur following surgical procedures, injuries and other medical events, and its treatment requirements vary according to the cause, intensity, duration and characteristics of the patient.
A broader indication could also increase the potential clinical applications of the product if supported by appropriate evidence. However, the proposed scope of development should not be confused with an approved indication. AlgiaPak remains investigational, and its safety and efficacy for any particular type of acute pain must be established through clinical development and regulatory review.
The company has also stated that it intends to apply for FDA Fast Track designation. Fast Track is designed to facilitate the development and expedite the review of medicines intended to treat serious conditions and address unmet medical needs. Eligibility and any resulting benefits are determined by the FDA; an intention to apply does not mean that designation has been granted.
Phase 2a Trial Planned in Patients Undergoing Bunionectomy
Following the planned IND submission, Algia expects to initiate a Phase 2a randomized, double-blind clinical trial in the first quarter of 2027, provided the necessary regulatory clearance is obtained.
The proposed study will evaluate AlgiaPak in patients experiencing mild-to-moderate acute pain following bunionectomy. The procedure corrects a bunion, a deformity involving the joint at the base of the big toe, and provides a defined surgical setting in which postoperative pain management can be investigated.
A clinical study in this population could help researchers assess whether the multimodal regimen provides meaningful pain relief after surgery and how its performance compares with the treatment approach specified in the final protocol. The exact study design, including its comparator, endpoints, sample size and statistical analysis, will be determined by the clinical protocol and regulatory requirements.
Randomization assigns participants to study groups according to a predefined process, helping reduce selection bias. A double-blind design means that participants and specified study personnel do not know which treatment participants receive, where appropriate under the protocol. These methods can help reduce bias when assessing treatment outcomes, although the quality and interpretability of the results also depend on trial execution and analysis.
The planned Phase 2a study is an important step in determining whether the preclinical rationale for AlgiaPak translates into a useful treatment option for people with acute pain. It may also help inform subsequent development decisions, including the need for additional studies, dose optimization and evaluation in other acute pain populations.
Algia’s target timeline remains conditional. The company must complete its IND submission, address applicable regulatory requirements and ensure that the trial is operationally ready before patient enrollment can begin. Funding availability and other clinical-development considerations may also affect timing.
A Multimodal Approach to Non-Opioid Pain Management
AlgiaPak is designed around multimodal pain management, an approach that combines medicines acting through different mechanisms to address pain. Instead of relying on a single medicine or pharmacological pathway, multimodal strategies aim to use complementary treatments to achieve pain control.
The company describes AlgiaPak as a combination of multiple well-established, clinically proven medicines that target non-opioid pain receptors. These medicines are brought together in a single prescribing and dosing format intended to standardize hospital-grade multimodal pain management for outpatient use.
The rationale is to make a regimen that may be familiar in clinical pain management easier to prescribe and follow after patients leave a hospital or surgical facility. In outpatient care, patients can face practical challenges when multiple medicines require different dosing times, instructions and prescriptions. A simplified regimen could help reduce this complexity.
Algia intends for AlgiaPak to be prescribed as a single regimen rather than requiring clinicians to issue multiple prescriptions with separate dosing schedules. The company believes this format could improve ease of use and adherence, while providing a consistent approach to managing mild-to-moderate acute pain.
Nevertheless, the effectiveness of a multimodal regimen depends on the specific medicines included, their doses, the population being treated and the clinical context. The proposed advantages of a simplified prescription format will also need to be evaluated in practice. A single prescribing format does not, by itself, establish that patients will adhere more consistently or achieve better outcomes.
If clinical studies demonstrate that AlgiaPak can provide effective pain relief with an acceptable safety profile, the product could offer clinicians another option for acute pain management. Its proposed role would be to expand the available non-opioid treatment choices, rather than to suggest that opioids have no place in pain care.
Addressing the Risks Associated With Opioid Exposure
The development of alternative pain treatments is taking place against the backdrop of the continuing global burden of drug overdose and opioid-related harm.
Algia cited estimates indicating that more than 500,000 people die from drug overdoses worldwide each year, including more than 100,000 deaths in the United States. The company also referenced research suggesting that up to 10% of patients exposed to opioids in clinical care may develop addiction. These figures highlight the broader public health concerns surrounding drug-related harm, although overdose deaths and the risk of developing addiction are distinct measures and can vary by population, study design and the substances involved.
Opioids can be effective for certain types of pain, including severe acute pain and some forms of cancer-related pain. Their use requires clinical judgment, however, because risks can include sedation, respiratory depression, physical dependence, misuse and opioid use disorder. The risk profile differs among patients and is influenced by factors such as dose, duration of treatment, medical history and other medications.
Algia also pointed to U.S. prescribing data showing that clinicians wrote nearly 142 million opioid pain prescriptions in 2020. The company argues that greater use of standardized multimodal non-opioid regimens could help reduce reliance on opioids for mild-to-moderate acute pain, particularly in outpatient settings.
Although multimodal approaches have been used in clinical practice, Algia identifies a gap between their use in hospital environments and their consistent implementation after discharge. The company believes the absence of standardized, easy-to-prescribe outpatient regimens has limited broader access and adoption.
AlgiaPak is being developed to address that implementation challenge by combining multiple medicines into a single regimen with a defined dosing format. If successful, this model could simplify the transition from hospital-based pain management to treatment at home, where patients and caregivers may be responsible for following medication instructions without continuous clinical supervision.
The potential public health contribution of AlgiaPak will depend on evidence demonstrating adequate pain control, an acceptable safety profile and practical benefits in the intended patient populations. It will also be important to determine whether the regimen can reduce opioid use or exposure in real-world settings rather than assuming that a non-opioid product automatically produces that outcome.
Intellectual Property and Pricing Strategy
Alongside its clinical and regulatory work, Algia has established an intellectual property position for AlgiaPak. The company reports that it has secured three issued U.S. patents, with additional patent filings underway in the United States and Europe.
Patents can help protect aspects of a pharmaceutical product, formulation or delivery approach, depending on the claims granted by the relevant patent offices. The scope and duration of protection depend on the specific patents and applicable laws. Algia’s additional filings indicate that the company continues to pursue intellectual property protection as it advances development.
The company is also developing a pricing strategy intended to make AlgiaPak competitive with opioid prescriptions. Algia’s stated goal is to create an accessible non-opioid pain treatment that can be considered for a broad range of mild-to-moderate acute pain settings.
Affordability could influence uptake if the product eventually reaches the market, particularly where clinicians, hospitals, insurers and patients must consider the cost of treatment alongside clinical outcomes. However, final pricing, reimbursement arrangements and market access will depend on the product’s eventual regulatory status, clinical evidence, manufacturing costs and commercial strategy.
A competitive price alone will not determine adoption. Clinicians will need confidence in the product’s effectiveness, safety, dosing instructions and suitability for individual patients. Hospitals and outpatient providers will also need to assess how it fits into existing care pathways.
Next Steps for AlgiaPak
Algia’s completion of its GLP-compliant IND-enabling toxicology study marks progress toward its goal of advancing AlgiaPak into clinical development. The company is finalizing its regulatory dossier and expects to submit an IND application to the FDA by the end of 2026.
Subject to regulatory clearance, Algia plans to begin a Phase 2a randomized, double-blind study in patients with mild-to-moderate acute pain following bunionectomy in the first quarter of 2027. The company is also seeking funding to support the clinical program and intends to pursue Fast Track designation.
The development strategy combines a multimodal non-opioid treatment approach with a simplified prescribing format, a proposed 505(b)(2) regulatory pathway and an effort to address the practical barriers that can complicate outpatient pain management.
For now, the toxicology findings provide preclinical support rather than proof of clinical benefit. The next major milestone will be the FDA’s consideration of the IND submission and, if the study proceeds, the generation of human data on AlgiaPak’s safety and efficacy.
As the search for effective alternatives to opioid-based treatment continues, Algia is positioning AlgiaPak as a potential option for mild-to-moderate acute pain. Whether the regimen can deliver on that promise will depend on the results of its clinical trials, its eventual regulatory review and its ability to demonstrate meaningful benefits for patients and healthcare providers.
About Algia Pharma
Algia Pharma is a pharmaceutical company dedicated to reducing opioid exposure across the healthcare system by making hospital-grade multimodal pain control available, practical, and affordable in everyday outpatient care. Algia is developing the AlgiaPak®, a simple, multimodal pain regimen designed to treat mild-to-moderate acute pain as effectively as opioids without addiction risk. The company was founded by two anesthesiologists, Hannah Thompson, M.D., and Joseph Loskove, M.D., and pharmacist David Steinberg, Pharm.D., J.D., who together have decades of front-line experience in pain management.